Current Problems in Surgery
Volume 43, Issue 10 , Pages 685-765 , October 2006

Islet Cell Tumors

References 

  1. Buchanon KD, Johnston CF, O’Hare MMT, et al. Neuroendocrine tumours: a European view. Am J Med. 1986;81:14–22
  2. Solcia E, Capella C, Klöppel G. Tumors of the Pancreas. Washington DC: Armed Forces Institute of Pathology; 1997;3rd series
  3. Heitz PU, Klöppel G. Pancreatic endocrine tumors. Path Res Pract. 1988;183:155–168
  4. Greider MH, Elliott DW. Electron microscopy of human pancreatic tumors of islet cell origin. Am J Pathol. 1964;44:663–678
  5. Lloyd RV, Mervak T, Schmidt K, Warner TFCS, Wilson BS. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol. 1984;8:607–614
  6. Tapia FJ, Barbosa AJA, Marangos PJ, Polak JM, Bloom SR, Dermody C. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet. 1981;2:808–811
  7. Capella C, Hietz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425:547–560
  8. Heymann MF, Joubert M, Nemeth J, et al. Prognostic and immunohistochemical validation of the Capella classification of pancr4eatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology. 2000;36:421–432
  9. Klöppel G, Hietz PU, Capella C, Solcia E. Endocrine tumors of the pancreas. In:  Solcia E,  Klöppel G,  Sobin LH editor. in collaboration with 9 pathologists from 4 countries. Histological Typing of Endocrine Tumours. 2nd ed.. Heidelberg: Springer-Verlag; 2000;p. 56–60
  10. Compton CC. Diseases of the pancreas. In:  Weidner N editors. The difficult diagnosis in surgical pathology. Philadelphia: WB Saunders; 1996;p. 270–272
  11. Solcia E, Capella C, Fiocca R, Cornaggis M, Bosi F. The gastroenteropancreatic endocrine system and related tumors. Gastroenterol Clin North Am. 1989;18:671–693
  12. Graeme-Cook F, Bell DA, Flotte I-J, et al. Aneuploidy in pancreatic insulinomasdoes not predict malignancy. Cancer. 1990;66:2365–2368
  13. Donow C, Baisch H, Heitz PU, Klöppel G. Nuclear DNA content in 27 pancreatic endocrine tumors: correlation with malignancy, survival and expression of glycoprotein hormone alpha chain. Virchows Arch. 1991;419:463–468
  14. Pelosi G, Zamboni G, Doglioni C, et al. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignant in endocrine tumors of the pancreas. Am J Surg Pathol. 1992;16:1215–1225
  15. Clarke MR, Baker EE, Weyant RJ, Hill L, Carty SE. Proliferative activity in pancreatic endocrine tumors: association with function, metastases and survival. Endocr Pathol. 1997;8:181–187
  16. Fisher WE, Brunicardia FC. Zollinger-Ellison syndrome. In:  Cameron J editors. Current Surgical Therapy. 8th ed.. Philadelphia, PA: Mosby; 2004;p. 76–79
  17. Roy P, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine. 2000;79:379–411
  18. Modlin IM, Jaffe BM, Sank A, Albert D. The early diagnosis of gastrinoma. Ann Surg. 1982;196:512–517
  19. Townsend CM, Thompson JC. Up-to-date treatment of patients with gastrinoma. Adv Surg. 1987;20:155–181
  20. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–644
  21. Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: reappraisal and evaluation of 260 registered cases. Ann Surg. 1964;160:512–530
  22. Norton JA, Doppman JL, Collen MJ, et al. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg. 1986;204:468–479
  23. Soga J, Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg. 1998;5:77–85
  24. Cameron AJ, Hoffman HN. Zollinger-Ellison syndrome; clinical features and long-term follow-up. Mayo Clin Proc. 1974;49:44–51
  25. Christlieb AR, Schuster MM. Zollinger-Ellison syndrome. Arch Intern Med. 1964;114:381–388
  26. Ellison EH, Wilson SD. The Zollinger-Ellison syndrome: re-appraisal and evaluation of 260 registered cases. Ann Surg. 1964;160:512–530
  27. Farley DR, Van Heerden JA, Grant CS, Miller LJ, Ilstrup DM. The Zollinger-Ellison syndrome (A collective surgical experience). Ann Surg. 1992;215:561–569
  28. Kaplan EL, Horvath K, Udekwu A, Straus F, Schark C, Ferguson DJ, et al. Gastrinomas: a 42-year experience. World J Surg. 1990;14:365–375
  29. Regan PT, Malagelada JR. A reappraisal of clinical, roentgenographic, and endoscopic features of the Zollinger-Ellison syndrome. Mayo Clin Proc. 1978;53:19–23
  30. Stage JG, Stadil F. The clinical diagnosis of the Zollinger-Ellison syndrome. Scand J Gastroenterol. 1979;53:79–91
  31. Thompson JC, Reeder DD, Villar HV, Fender HR. Natural history and experience with diagnosis and treatment of the Zollinger-Ellison syndrome. Surg Gynecol Obstet. 1975;140:721–739
  32. Way L, Goldman L, Dunphy JE. Zollinger-Ellison syndrome (An analysis of twenty-five cases). Am J Surg. 1968;116:293–304
  33. Lenert JT, Bold RJ, Sussman JJ, Tyler DS. Pancreatic endocrine tumors and multiple endocrine neoplasia. In:  Feig B,  Berger DH,  Fuhrman GM editor. The MD Anderson Surgical Oncology Handbook. 3rd ed.. Philadelphia: Lippincott Williams & Wilkins; 2004;p. 324–351
  34. Ellison EC, Sparks J. Zollinger-Ellison syndrome in the era of effective acid suppression: are we unknowingly growing tumors?. Am J Surg. 2003;186:245–248
  35. Corleto VD, Annibale B, Gibril F, Angeletti S, Serrano J, Venzon DJ, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?. Aliment Pharmacol Ther. 2001;15:1555–1561
  36. Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, Venzon DJ, Metz DC, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Int Med. 1993;119:199–206
  37. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome (Current concepts in diagnosis and management). N Engl J Med. 1987;317:1200–1209
  38. McGuigan JE, Trudeau WL. Immunochemical measurement of elevated levels of gastrin in the serum of patients with pancreatic tumors of the Zollinger-Ellison variety. N Engl J Med. 1968;278:1308–1318
  39. Jensen RT, Gardner JD, Raufman JP. Zollinger-Ellison syndrome: NIH combined clinical staff conference. Ann Intern Med. 1983;98:59–75
  40. Meko JB, Norton JA. Gastrinoma. In:  Beger HG,  Warshaw AL,  Büchler MW,  Carr-Locke DL,  Neoptolemos JP,  Russell C, et al. editor. The Pancreas. Oxford: Blackwell Science; 1988;p. 1228–1253
  41. Frucht H, Howard JM, Slaff JE, et al. Secretin and calcium provocative tests in patients with Zollinger-Ellison syndrome: a prospective study. Ann Intern Med. 1989;111:713–722
  42. Deveney CW, Deveney KS, Jaffe BM, et al. Use of calcium and secretin in the diagnosis of gastrinoma (Zollinger-Ellison syndrome). Ann Intern Med. 1977;87:680–686
  43. Jensen RT. Zollinger-Ellison syndrome. In:  Doherty GM,  Skogscid B editor. Surgical Endocrinology: Clinical Syndromes. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 291–344
  44. Alexander HR, Fraker DL, Norton JA, Bartlett DL, Tio L, Benjamin SB, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998;228:228–238
  45. Cadiot G, Lebtahi R, Sarda L, Bonnaud G, Marmuse JP, Vissuzaine C, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology. 1996;111:845–854
  46. Frucht H, Norton JA, London JF, Vinayek R, Doppman JL, Gardner JD, et al. Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology. 1990;99:1622–1627
  47. Howard TJ, Zinner MJ, Stabile BE, Passaro E. Gastrinoma excision for cure: a prospective analysis. Ann Surg. 1990;211:9–14
  48. Jordan PH. A personal experience with pancreatic and duodenal neuroendocrine tumors. J Am Coll Surg. 1999;189:470–482
  49. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg. 1992;215:8–18
  50. Sugg SL, Norton JA, Fraker DL, Metz DC, Pisegna JR, Fishbeyn V, et al. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg. 1993;218:138–144
  51. Weber HC, Venzon DJ, Lin JT, Fishburn VA, Orbuch M, Strader DB, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1637–1649
  52. Zogakis TG, Gibril F, Libutti SK, Norton JA, White DE, Jensen RT, et al. Management and outcome of patients with sporadic gastrinomas arising in the duodenum. Ann Surg. 2003;238:42–48
  53. Maton PN, Mackem SM, Norton JA, Gardner JD, O’Dorisio TM, Jensen RT. Ovarian carcinoma as a cause of Zollinger-Ellison syndrome: natural history, secretory products, and response to provocative tests. Gastroenterology. 1989;97:468–471
  54. Wu PC, Alexander HR, Bartlett DL, Doppman JL, Fraker DL, Norton JA, et al. A prospective analysis of the frequency, location and curability of ectopic (nonpancreaticoduodenal nonnodal) gastrinoma. Surgery. 1997;122:1176–1182
  55. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, et al. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615–630
  56. Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumors: importance and recent advances. Dig Liver Dis. 2002;34:668–680
  57. Serrano J, Goebel SU, Peghni PL, Lubensky IA, Gibril F, Jensen RT. Alterations in the p16 INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab. 2000;85:4146–4156
  58. Goebel SU, Heppner C, Burns AL, Marx SJ, Spiegel AM, Zhuang Z, et al. Genotype/phenotype correlations of MEN1 gene mutations in sporadic gastrinoma. J Clin Endocrinol Metab. 2000;85:116–123
  59. Muscarella P, Melvin WS, Fisher WE, For J, Ellison EC, Harman JG, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res. 1998;58:237–240
  60. Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, et al. Her2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res. 2002;62:3702–3710
  61. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res. 2002;8:2273–2285
  62. Sutliff VE, Doppman JL, Gibril F, Yu F, Serrano J, Venzon DJ, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol. 1997;15:2420–2431
  63. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy. Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1006;125:26-34.
  64. de Kerviler E, Cadiot G, Lebtahi R, Faraggi M, Le Guludec D, Mignon M. Somatostain receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome (GRESZE: Groupe d’Etude du Syndrome de Zollinger-Ellison). Eur J Nucl Med. 1994;21:1191–1197
  65. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757–773
  66. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70–78
  67. Foley WD, Mallisee TA, Hohenwalter MD, Wilson CR, Quiroz FA, Taylor AJ. Multiphase hepatic CT with a multirow detector CT scanner. AJR Am J Roentgenol. 2000;175:679–685
  68. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology. 1998;206:143–150
  69. Donow C, Pipeleers-Marichal M, Schroder S, Stamm B, Heitz PU, Kloppel G. Surgical pathology of gastrinoma: site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer. 1991;68:1329–1334
  70. DeAngelis C, Carucci P, Repici A, Rizzetto M. Endosonography in decision making and management of gastrointestinal endocrine tumors. Eur J Ultrasound. 1999;10:139–150
  71. Proye C, Malvaux P, Pattou F, Filoche B, Godchaux JM, Maunoury V, et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery. 1998;124:1134–1144
  72. Ruszniewski P, Amouyal P, Amouyal G, Grange JD, Mignon M, Bouche O, et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery. 1995;117:629–635
  73. Zimmer T, Stolzel U, Bader M, Koppenhagen K, Hamm B, Buhr H, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Gut. 1996;39:562–568
  74. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271–2277
  75. Norton JA, Alexander HR, Fraker DL, Venzon DL, Gibril F, Jensen RT. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234:495–506
  76. Wamsteker EJ, Gauger PG, Thompson NW, Scheiman JM. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc. 2003;58:531–535
  77. Gauger PG, Thompson NW. Early surgical intervention and strategy in patients with multiple endocrine neoplasia type 1. Best Pract Res Clin Endocrinol Metab. 2001;15:213–223
  78. Thompson NW. Multiple endocrine neoplasia type I: surgical therapy. Cancer Treat Res. 1997;89:407–419
  79. McHenry CR. Pancreatic islet cell tumors. In:  Baker RJ,  Fischer JE editor. Mastery of Surgery. 4th ed.. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 552–559
  80. Ellison EC, Carey LC, Sparks J, O’Dorisio TM, Mekhjian HS, Fromkes JJ, et al. Early surgical treatment of gastrinoma. Am J Med. 1987;82:17–24
  81. Ellison EC. Forty year appraisal of gastrinoma: back to the future. Ann Surg. 1995;222:511–524
  82. Fraker DL, Jensen RT. Pancreatic endocrine tumors. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott-Raven; 1997;p. 1678–1704
  83. Brentjens R, Saltz L. Islet cell tumors of the pancreas (The medical oncologist’s perspective). Surg Clin North Am. 2001;81:527–554
  84. Norton JA, Cromack DT, Shawker TH, Doppman JL, Comi R, Gorden P, et al. Intraoperative ultrasonographic localization of islet cell tumors (A prospective comparison to palpation). Ann Surg. 1988;207:160–168
  85. Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol. 2003;12:145–151
  86. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the routine use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?. Ann Surg. 2004;239:617–625
  87. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Does the routine use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?. Ann Surg. 2004;239:617–625
  88. Jensen RT, Fraker DL. Zollinger-Ellison syndrome: advances in treatment of the gastric hypersecretion and the gastrinoma. JAMA. 1994;271:1–7
  89. Berends FJ, Cuesta MA, Kazemier G, van Eijck CH, de Herder WW, Bruining HA, et al. Laparoscopic detection and resection of insulinomas. Surgery. 2000;128:386–391
  90. Fernandez-Cruz L, Saenz A, Astudillo E, Martinez I, Hoyos S, Pantoja JP, et al. Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg. 2002;26:1057–1065
  91. Furihata M, Tagaya N, Kubota K. Laparoscopic enucleation of insulinoma in the pancreas: case report and review of the literature. Surg Laparosc Endosc Percutan Tech. 2001;11:279–283
  92. Iihara M, Kanbe M, Okamoto T, Ito Y, Obara T. Laparoscopic ultrasonography for resection of insulinomas. Surgery. 2001;130:1086–1091
  93. Spitz JD, Lilly MC, Tetik C, Arregui ME. Ultrasound-guided laparoscopic resection of pancreatic islet cell tumors. Surg Laparosc Endosc Percutan Tech. 2000;10:168–173
  94. Underwood RA, Soper NJ. Current status of laparoscopic surgery of the pancreas. J Hepatobil Pancreat Surg. 1999;6:154–164
  95. Iihara M, Kanbe M, Okamoto T, Ito Y, Obara T. Laparoscopic ultrasonography for resection of insulinomas. Surgery. 2001;130:1086–1091
  96. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757–773
  97. Alexander HR, Bartlett DL, Venzon DJ, Libutti SK, Doppman JL, Fraker DL, et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery. 1998;124:1153–1159
  98. Fishbeyn VA, Norton JA, Benya RV, Pisegna JR, Venzon DJ, Metz DC, et al. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: the best approach. Ann Intern Med. 1993;119:199–206
  99. Pisegna JR, Norton JA, Slimak GG, Metz DC, Maton PN, Jensen RT. Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology. 1992;102:767–778
  100. Metz DC, Benya RV, Fishbeyn VA, Pisegna JR, Obruch M, Strader DB, et al. Prospective study of the need for long-term antisecretory therapy in patients with Zollinger-Ellison syndrome following successful curative gastrinoma resection. Aliment Pharmacol Ther. 1993;7:247–257
  101. Perry RR, Vinik AI. Endocrine tumors of the gastrointestinal tract. Annu Rev Med. 1996;47:57–68
  102. Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin of North Am. 2001;81:511–525
  103. Alexander HR, Jensen RT. Pancreatic endocrine tumors. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott-Raven; 1997;p. 1788–1813
  104. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422–427
  105. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer. 1990;65:1883–1890
  106. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992;112:1024–1031
  107. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096
  108. Nagorney DM, Que FG. Cytoreductive hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. In:  Mignon M,  Jensen RT editor. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management: Series: Frontiers of Gastrointestinal Research. Switzerland: Karger, Basel; 1995;p. 416–430
  109. Norton JA, Sugarbaker PH, Doppman JL, Wesley RA, Maton PN, Gardner JD, et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg. 1986;203:352–359
  110. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375–382
  111. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–1065
  112. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36–43
  113. Thom AK, Norton JA, Doppman JL, Miller DL, Chang R, Jensen RT. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1002;112:1002-8.
  114. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastasis: does intervention alter outcomes?. J Am Coll Surg. 2000;190:432–445
  115. McEnter GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096
  116. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993;7:597–610
  117. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103:1498–1508
  118. Service FJ, McMahon MM, O’Brien PC, et al. Functioning insulinoma-incidence, recurrence and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711–719
  119. Whipple AO, Franz VK. Adenoma of islet cells with hyperinsulinism. Am Surg. 1935;101:1299–1355
  120. Grant CS. Insulinoma. Surg Oncol Clin North Am. 1998;7:819–844
  121. Service FJ, Dale AJD, Elveback IR, et al. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc. 1976;51:417–429
  122. Arnold R, Frank M, Bülchman G. Insulinoma and persistent neonatal hyperinsulinemic hypoglycemia (nesidioblastosis). In:  Beger HG,  Warshaw AL,  Bücher MW,  Carr-Locke DL,  Neoptolemos JP,  Russel C, et al. editor. The Pancreas. Oxford: Blackwell Science; 1998;p. 1187–1202
  123. Turner RC, Keding I. Plasma proinsulin, C-peptide and insulin in diagnostic suppression test for insulinomas. Diabetologia. 1977;13:571–577
  124. Boukhman MP, Karam JM, Shaver J, Siperstein AE, DeLorimier AA, Clark OH. Localization of insulinomas. Arch Surg. 1999;134:818–823
  125. Gianello P, Gigot JF, Berthet F, et al. Pre- and intraoperative localization of insulinomas: report of twenty-two observations. World J Surg. 1988;12:389–397
  126. Doherty GM, Doppman JL, Shawker TH, et al. Results of a prospective strategy to diagnose, localize and resect insulinomas. Surgery. 1991;110:989–997
  127. Bottger TC, Weber W, Beyer J, Junginger T. Value of tumor localization in patients with insulinoma. World J Surg. 1990;14:107–114
  128. Felder JL, Fletcher JG, Reading CC, et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol. 2003;181:775–780
  129. Theoni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology. 2000;214:483–490
  130. Catalano C, Pavone P, Laghi A, et al. Localization of pancreatic insulinomas with MR imaging at 0.5 T. Acta Radiol. 1999;40:644–648
  131. Grant CS. Surgical aspects of hyperinsulinemic hypoglycemia. Endocrinol Clin North Am. 1999;28:533–554
  132. Bansal R, Tierney W, Carpenter S, Thompson N, Scheiman JM. Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc. 1999;49:19–25
  133. Gouya H, Vignaux O, Augui J. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003;181:987–992
  134. Bertherat F, Tenenbaum K, Perlemoine C, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab. 2003;88:5353–5360
  135. Lamberts SW, Kenning EP, Reubi JC. The role of somatostatin and its analogues in the diagnosis and treatment of tumors. Endocr Rev. 1991;12:450–482
  136. Perry RR, Vinik AI: Diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1195;80:2273-78.
  137. Schillaci O, Massa R, Scopinaro F. 111In-pentecreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med. 2000;41:459–462
  138. Won JGS, Tseng H-S, Yan A-H, et al. Intra-arterial calcium stimulation test for detection of insulinomas: Detection rate, responses to pancreatic peptides, and its relationship to differentiation of tumor cells. Metabolism. 2003;52:1320–1329
  139. Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg. 2001;136:1020–1025
  140. Imamura M, Takahashi K, Adashi H, et al. Usefulness of selective arterial secretin injection test for localization of gastrinomas in the Zollinger-Ellison syndrome. Ann Surg. 1987;205:230–239
  141. Doppman JL, Miller JL, Chang R, et al. Insulinoma: Localization with selective intraarterial injection of calcium. Radiology. 1991;178:237–2411991
  142. Prentki M, Matschinsky FM. Ca2+, cAMP, and phospholipids-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev. 1987;67:1185–1248
  143. Brown CK, Bartlett DL, Doppman JL, et al. Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery. 1997;122:1189–1194
  144. Rothmund M, Angelini L, Brunt M, et al. Surgery for benign insulinoma: an international review. World J Surg. 1990;14:393–399
  145. Grant CS, vanHeerden JA, Charboneau JW, et al. Insulinoma: the value of intraoperative ultrasonography. Arch Surg. 1988;123:843–847
  146. Carniero DM, Levi JU, Irvin GL. Rapid insulin assay for intraoperative confirmation of complete resection of insulinomas. Surgery. 2002;132:937–943
  147. Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am. 1989;18:45–74
  148. Stefanini P, Carboni M, Patrassi N, Basoli A. Beta-islet cell tumors of the pancreas: results of a study on 1067 cases. Surgery. 1974;75:597–609
  149. Sarr MG Pancreatic Surgery Group. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. JACS. 2003;196:556–565
  150. Gagner M, Pomp A, Herrera MF. Early experience with laparoscopic resections of islet cell tumors. Surgery. 1996;120:1051–1054
  151. Fernandez-Cruz L, Sáenz A, Astudillo E, et al. Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg. 2002;26:1057–1065
  152. Berends FJ, Cuesta MA, Kazemier G, et al. Laparoscopic detection and resection of insulinomas. Surgery. 2000;128:386–391
  153. Park AE, Heniford BT. Therapeutic laparoscopy of the pancreas. Ann Surg. 2002;236:149–158
  154. Kaplan EL, Lee C-H. Recent advances in the diagnosis and treatment of insulinomas. Surg Clin North Am. 1979;59:119–129
  155. Thompson GB. Insulinoma. In:  Prinz RA,  Staren ED editor. Endocrine Surgery. Endocrine Surgery. Georgetown TX: Landes Bioscience; 2000;p. 222–228
  156. Harrison TS, Child CG, Fry WJ, et al. Current surgical management of functioning islet-cell tumors of the pancreas. Ann Surg. 1973;178:485–495
  157. Kaplan EL, Lee C-H. Recent advancements in the diagnosis and treatment of insulinomas. Surg Clin North Am. 1979;59:119–129
  158. Proye CA, Pattou F, Carnaille B, Lefebvre J, Decoulx M, d’Herbomez M. Intraoperative insulin measurement during surgical management of insulinomas. World J Surg. 1998;22:1218–1224
  159. Stefanini P, Carboni M, Patrassi N, Basoli A. Hypoglycemia and insular hyperplasia. Ann Surg. 1974;180:130–135
  160. Harrison TS, Fajans SS, Floyd JC, et al. Prevalence of diffuse pancreatic beta islet cell disease with hyperinsulinism: problems in recognition and management. World J Surg. 1984;8:583–589
  161. Thompson GB, Service FJ, Andrews JC, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. Surgery. 2000;128:937–945
  162. Service FJ, McMahon MM, O’Brien PC, et al. Functioning insulinoma-incidence, recurrence and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711–719
  163. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096
  164. Soga J. The Niigata registry for gut-pancreatic endocrinomas: maintenance, analysis and supply with Windows version. Bull Niigata Seiryo Univ. 2004;4:39–55
  165. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959
  166. Pataky Z, Nagy L, Popik E. Uber einen vomPankreaskopf hervorgehenden primarin Argentaffintumorbefall. Zentralbl Allg Pathol. 1959;99:442–444
  167. Soga J. Carcinoids of the pancreas: an analysis of 156 cases. Cancer. 2005;104:1180–1187
  168. Verner JV, Morrison AB. Non-beta islet cell tumors and the syndrome of watery diarrhea, hypokalemia, and hypochlorhydria. Clin Gastroenterol. 1974;3:595–608
  169. Murray JS, Paton RR, Pope CE. Pancreatic tumor associated with flushing and diarrhea. N Engl J Med. 1961;264:436–439
  170. Verner JV, Morrison AB. Endocrine pancreatic islet cell disease with diarrhea: report of a case due to diffuse hyperplasia of non-beta islet tissue with a review of 54 additional cases. Arch Intern Med. 1974;133:492–500
  171. Capella C, Polak JM, Buffa R, et al. Morphological patterns and diagnostic criteria of VIP producing endocrine tumors: a histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer. 1983;52:1860–1874
  172. O’Dorisio TM, Mekjian HS. VIPoma syndrome. In:  Cohen S,  Soloway RD editor. Contemporary Issues in Gastroenterology. New York: Churchill Livingstone; 1984;p. 101–116
  173. Fausa O, Fretheim B, Elgjo K, et al. Intractable watery diarrhea, hypokalemia, and achlorhydria associated with non-pancreatic retroperitoneal neurogenous tumour containing vasoactive intestinal peptide. Scand J Gastroenterol. 1973;8:713–717
  174. Said SI, Faloona GR. Elevated plasma and tissue levels of vasoactive intestinal peptide in watery diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N Engl J Med. 1975;293:155–160
  175. Watson KJR, Shulkes A, Smallwood RA, et al. Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus. Gastroenterology. 1985;88:798–803
  176. Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med. 1988;319:605–607
  177. Edney JA, Hofmann S, Thompson JS, Kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entity. Am J Surg. 1990;160:625–629
  178. Prinz RA, Sagimoto J, Lorincz A, et al. Glucagonoma. In:  Howard JM,  Jordan GL,  Reber HA editor. Surgical Diseases of the Pancreas. Philadelphia: Lea & Febiger; 1987;p. 848–857
  179. Prinz RA, Dorsch TR, Lawrence AM, et al. Clinical aspects of glucagon producing islet cell tumors. Am J Gastroenterol. 1981;76:125–131
  180. Bordi C, Yu JY, Girolami A, et al. Immunohistochemical localization of factor X-like antigen in pancreatic islets and their tumours. Virchows Arch A. 1990;416:397–402
  181. Altimari AF, Bhoopalam N, O’Dorisio T, Lange CL, Sandberg L, Prinz RA. Use of somatostatin analogue (SMS 201-995) in the glucagonoma syndrome. Surgery. 1986;100:989–996
  182. Krejs GS, Orchi L, Conlon JM, et al. Somatostatinoma syndrome: biochemical, morphologic and clinical features. N Engl J Med. 1979;301:285
  183. Vinik AL, Strodel WE, Eckhauser FE, et al. Somatostatinomas, VIPomas and neurotensinomas. Semin Oncol. 1987;14:263–281
  184. Konomi K, Chijiwa K, Katsuta T, et al. Pancreatic somatostatinoma: a case report and review of the literature. J Surg Oncol. 1990;43:259
  185. Larsson LI, Holst JJ, Kuhl C, et al. Pancreatic somatostatinoma: clinical features and physiological implications. Lancet. 1977;1:666–669
  186. Eckhause FE, Colletti LM. Somatostatinoma. In:  Beger HG,  Warshaw AL,  Büchler MW,  Carr-Locke DL,  Neoptolemos JP,  Russell C, et al. editor. The Pancreas. London: Blackwell Science; 1998;p. 1270–1274
  187. Orth DN. Cushing’s syndrome. N Engl J Med. 1995;332:791–803
  188. Amikura K, Alexander HR, Norton JA, et al. Role of surgery in management of adrenocorticotropic hormone-producing islet cell tumors of the pancreas. Surgery. 1995;118:1125–1130
  189. Clark ES, Carney JA. Pancreatic islet cell tumor associated with Cushing’s syndrome. Am J Surg Pathol. 1984;8:917–924
  190. Graham BS, Tucker WS. Opportunistic infections in endogenous Cushing’s syndrome. Ann Intern Med. 1984;101:334–338
  191. Law DH, Liddle GW, Scott W, Tauber SD. Ectopic production of multiple hormones (ACTH, MSH and gastrin) by a single malignant tumor. N Engl J Med. 1965;273:292–296
  192. Mao C, Carter P, Schaefer P, et al. Malignant islet cell tumor associated with hypercalcemia. Surgery. 1995;117:37–40
  193. Miraliakbari BA, Asa SL, Boudreau SF. Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Hum Pathol. 1992;23:884–887
  194. Kao PC, Klee GG, Taylor RL, Heath H. Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions. Mayo Clin Proc. 1990;65:1399–1407
  195. Wynick D, Ratcliffe WA, Heath DA, et al. Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone related peptide. BMJ. 1990;300:1314–1315
  196. Evans DB, Skibber JM, Lee JF, et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993;114:1175–1181
  197. Solorzano CC, Lee JF, Pister PWT, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2000;130:1078–1085
  198. Merrell RC, Evans DB. In: 1st ed.. Pancreatic Polypeptide-Producing and Nonfunctioning Islet Cell Tumors of the Pancreas. The Pancreas. Vol. 2:Blackwell Science Ltd: Oxford; 1998;p. 1275–1283
  199. Bartsch DK, Schilling T, Ramaswamy A, et al. Management of nonfunctioning islet cell carcinomas. World J Surg. 2000;24:1418–1424
  200. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404–407
  201. Skogseid B, Rastad J, Akerstrom G. Pancreatic endocrine tumors in multiple endocrine neoplasia type 1. In:  Doherty G,  Skogseid B editor. Surgical Endocrinology. 1st ed.. New York: Lippincott Williams & Wilkins; 2001;p. 511–524
  202. Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res. 2005;37:369–374
  203. Alexakis N, Connor S, Ghaneh P, Lombard M, Smart HL, Evans J, et al. Hereditary pancreatic endocrine tumours. Pancreatology. 2004;4:417–433discussion 434-5
  204. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern. 1998;129:484–494
  205. Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Emmert-Buck MR, et al. Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1). J Intern Med. 1998;243:447–453
  206. Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res. 1999;54:397–438discussion 438-399
  207. MacFarlane MP, Fraker DL, Alexander HR, Norton JA, Lubensky I, Jensen RT. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery. 1995;118:973–979discussion 979-80
  208. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–644
  209. Alexander HR, Bartlett DL, Venzon DJ, Libutti SK, Doppman JL, Fraker DL, et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery. 1998;124:1160–1166
  210. Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85:3222–3226
  211. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease (Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both). J Intern Med. 1998;243:495–500
  212. Doherty G, Jensen RT. Multiple endocrine neoplasias. In:  Devita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles & Practice of Oncology. 7th ed.. New York: Lippincott Williams & Wilkins; 2005;p. 1575–1580
  213. Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995;123:269–273
  214. Doppman JL, Miller DL, Chang R, Gorden P, Eastman RC, Norton JA. Intraarterial calcium stimulation test for detection of insulinomas. World J Surg. 1993;17:439–443
  215. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab. 2001;12:173–178
  216. Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, Lubensky I, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery. 1998;124:1153–1159
  217. Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128:1022–1027discussion 1027-8
  218. Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol. 1998;153:223–231
  219. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059–2067
  220. Walther M, Linehan WM, Libutti SK. von Hippel-Lindau disease and von Recklinghausen’s cisease. In:  Doherty G,  Skogseid B editor. Surgical Endocrinology. 1st ed.. New York: Lippincott Williams & Wilkins; 2001;p. 581–591
  221. Na X, Wu G, Ryan CK, Schoen SR, di’Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol. 2003;170:588–592
  222. Wang YQ, Luk JM, Ikeda K, Man K, Chu AC, Kaneda K, et al. Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun. 2004;317:358–362
  223. Wheeler MH, Curley IR, Williams ED. The association of neurofibromatosis, pheochromocytoma, and somatostatin-rich duodenal carcinoid tumor. Surgery. 1986;100:1163–1169
  224. Mao C, Shah A, Hanson DJ, Howard JM. Von Recklinghausen’s disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol. 1995;59:67–73
  225. Sood GK, Chaudhry A, Malhotra V, Broor SL. Pancreatic cystadenoma associated with von Recklinghausen’s disease. Indian J Gastroenterol. 1991;10:148–149
  226. Lukash WM, Morgan RI, Sennett CO, Nielson OF. Gastrointestinal neoplasms in von Recklinghausen’s disease. Arch Surg. 1966;92:905–908
  227. Keller RT, Logan GM. Adenocarcinoma of the pancreas associated with neurofibromatosis. Cancer. 1977;39:1264–1266
  228. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem. 2003;278:5947–5951
  229. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, Bax NM, Ariyurek Y, Hermans CJ, et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr. 1999;158:284–287
  230. Knaebel HP, Diener MK, Wente MN, Buchler MW, Seiler CM. Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg. 2005;92:539–546
  231. Mabrut JY, Fernandez-Cruz L, Azagra JS, Bassi C, Delvaux G, Weerts J, et al. Hepatobiliary and Pancreatic Section (HBPS) of the Royal Belgian Society of Surgery Belgian Group for Endoscopic Surgery (BGES) Club Coelio Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery. 2005;137:597–605
  232. Patterson EJ, Gagner M, Salky B, Inabnet WB, Brower S, Edye M, et al. Laparoscopic pancreatic resection: single-institution experience of 19 patients. J Am Coll Surg. 2001;193:281–287
  233. Fernandez-Cruz L, Martinez I, Gilabert R, Cesar-Borges G, Astudillo E, Navarro S. Laparoscopic distal pancreatectomy combined with preservation of the spleen for cystic neoplasms of the pancreas. J Gastrointest Surg. 2004;8:493–501
  234. Dulucq JL, Wintringer P, Stabilini C, Feryn T, Perissat J, Mahajna A. Are major laparoscopic pancreatic resections worthwhile? (A prospective study of 32 patients in a single institution). Surg Endosc. 2005;19:1028–1034
  235. Gagner M, Pomp A. Laparoscopic pancreatic resection: is it worthwhile?. J Gastrointest Surg. 1997;1:20–26
  236. Kuroki T, Tajima Y, Kanematsu T. Surgical management for the prevention of pancreatic fistula following distal pancreatectomy. J Hepatobiliary Pancreat Surg. 2005;12:283–285
  237. Lin JW, Cameron JL, Yeo CJ, et al. Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg. 2004;8:951–959
  238. Efron DT, Lillemoe KD, Cameron JL, Yeo CJ. Central pancreatectomy with pancreaticogastrostomy for benign pancreatic pathology. J Gastrointest Surg. 2004;8:532–538
  239. Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg. 2004;139:718–725
  240. de Castro SM, Kuhlmann KF, Busch OR, et al. Delayed massive hemorrhage after pancreatic and biliary surgery: embolization or surgery?. Ann Surg. 2005;241:85–91
  241. Choi SH, Moon HJ, Heo JS, et al. Delayed hemorrhage after pancreaticoduodenectomy. J Am Coll Surg. 2004;199:186–191
  242. Horstmann O, Markus PM, Ghadimi MB, Becker H. Pylorus preservation has no impact on delayed gastric emptying after pancreatic head resection. Pancreas. 2004;28:69–74
  243. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg. 2000;190:432–445
  244. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36–42
  245. Choti MA, Bowman HM, Pitt HA, et al. Should hepatic resections be performed at high-volume referral centers?. J Gastrointest Surg. 1998;2:11–20
  246. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37
  247. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes. J Am Coll Surg. 2000;190:432–445
  248. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677–685
  249. Solorzano CC, Lee JE, Pisters PWT, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–1085
  250. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival. Ann Surg. 2005;241:776–785
  251. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KE, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–825
  252. Curley SA, Izzo F, Ellis LM, Vauthey JN, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhoses. Ann Surg. 2000;3:381–391
  253. Curley SA, Izzo F, Abdalla E, Vauthey JN. Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev. 2004;23:165–182
  254. Siperstein A, Garland A, Engle K, Rogers S, Berber E, Foroutani A, et al. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol. 2000;7:106–113
  255. Siperstein A, Garland A, Engle K, Rogers S, Berber E, String A, et al. Laparoscopic radiofrequency ablation of primary and metastatic liver tumors (Technical considerations). Surg Endosc. 2000;14:400–405
  256. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985–990
  257. Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26:1052–1056
  258. Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery. 1997;122:1147–1154
  259. Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol. 1998;14:175–183
  260. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25:693–696
  261. Le Truet YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report. Ann Surg. 1997;225:355–364
  262. Marlink RG, Lokich JJ, Robins JR, Clouse ME. Hepatic arterial embolization for metastatic hormone-secreting tumors (Technique, effectiveness, and complications). Cancer. 1990;15:2227–2232
  263. Clouse ME, Perry L, Stuart K, Stokes KR. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion. 1994;55:92–97
  264. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery. 1994;116:1111–1116
  265. Stokes KR, Stuart K, Clouse ME. Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol. 1993;4:341–345
  266. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol. 1998;170:339–344
  267. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors (A prospective phase II study in 24 patients). Cancer. 1993;71:2624–2630
  268. Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA. 1995;92:1580–1584
  269. Lamberts SWJ, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest. 1987;17:281–287
  270. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005;80:502–506
  271. Kvols LK, Reubi JC, Horisberger U, Moertel CG, Rubin J, Charboneau JW. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med. 1992;65:505–518
  272. Schally AV. Oncologic applications of somatostatin analogues. Cancer Res. 1985;48:6977–6985
  273. Wynick D, Bloom SR. The use of the long-acting somatostatin analogue octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab. 1991;73:1–3
  274. Kvols LK, Reubi JC, Horisberger U, Moertel CG, Rubin J, Charboneau JW. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med. 1992;65:505–518
  275. Lamberts SW, van der Lely AJ, de Herder WW, Hoflan LJ. Octreotide. N Engl J Med. 1996;334:246–254
  276. Wynick D, Anderson JV, Williams SJ, Bloom SR. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxf). 1989;30:385–388
  277. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautman ME. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth—the German Sandostatin Study Group. Digestion. 1992;54:72–75
  278. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276–3281
  279. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002;94:31–343
  280. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600–606
  281. Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. Cancer. 1993;72:3099–3105
  282. Schöber Ch, Schmoll E, Schmoll H-J, et al. Antitumour effect and symptomatic control with interferon α2b in patients with endocrine active tumours. Eur J Cancer. 1992;28A:1664–1666
  283. Biesma B, Willemse PHB, Mulder NH, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumors and tumor markers. Br J Cancer. 1992;66:850–855
  284. Faiss S, Pape UF, Böhmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanretotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689–2696
  285. Anthony LB, Woltering EA, Espanan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123–132
  286. Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110–122
  287. Reubi C, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–282
  288. Kwekkeboom DJ, Bakker WH, Kooij PP, Konynenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–1325
  289. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–2762
  290. Moertel C, Myrto L, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–523
  291. Gonzales MA, Biswas S, Corrie PG. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer. 2003;89:455–456
  292. Fenteany G, Schreiber SL. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. Chem Biol. 1996;3:905–912
  293. Shah MH, Young D, Kindler HL, et al. Phase II study of the proteosome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004;10:6111–6118
  294. Kegel T, Grothe W, Jordan K Graubner M, Arnold D, Schmoll J. Paclitaxel, carboplatin, and etoposide (TCE) in the treatment of advanced neuroendocrine tumours. Presented as an abstract at the 2005 meeting of the American Society of Clinical Oncology. Orlando, FL, May 13-17, 2005.
  295. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol. 1997;15:2385–2393
  296. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. Presented as an abstract at the 2005 meeting of the American Society of Clinical Oncology. Orlando, FL, May 13-17, 2005.
  297. Broder LE, Carter SK. Pancreatic islet cell carcinoma II (Results of therapy with streptozocin in 52 patients). Ann Intern Med. 1973;79:108–118
  298. Moertel CG, Lavin PT, Hahn RG. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep. 1982;66:1567–1569
  299. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189–1194
  300. Hoth D, Wooley B, Green D, Macdonald J, Schein P. Phase I studies on chlorozotocin. Clin Pharmacol Ther. 1978;23:712–722
  301. Eriksson B, Oberg K, Alm G, Karlson A, Lundqvist G, Anderson T, et al. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet. 1986;2:1307–1309
  302. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–523
  303. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86:944–948
  304. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998;21:36–38
  305. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–4771
  306. von Schrenck T, Howard JM, Doppman JL, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology. 1988;94:1326–1334

PII: S0011-3840(06)00075-X

doi: 10.1067/j.cpsurg.2006.07.003

Current Problems in Surgery
Volume 43, Issue 10 , Pages 685-765 , October 2006

Article Tools

* Image Usage & Resolution